FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting
You may also be interested in...
COX-2s drive OTCs at CVS
Sales of OTC NSAIDs and generic products are increasing at the pharmacy chain as a result of safety concerns surrounding COX-2s, CEO Thomas Ryan said during an earnings call Feb. 2. FDA's Arthritis Drug and Drug Safety & Risk Management advisory committees will evaluate COX-2 and NSAID safety during a meeting Feb. 16-18 (1"The Tan Sheet" Jan. 17, 2005, p. 9)...
COX-2s drive OTCs at CVS
Sales of OTC NSAIDs and generic products are increasing at the pharmacy chain as a result of safety concerns surrounding COX-2s, CEO Thomas Ryan said during an earnings call Feb. 2. FDA's Arthritis Drug and Drug Safety & Risk Management advisory committees will evaluate COX-2 and NSAID safety during a meeting Feb. 16-18 (1"The Tan Sheet" Jan. 17, 2005, p. 9)...
COX-2s drive OTCs at CVS
Sales of OTC NSAIDs and generic products are increasing at the pharmacy chain as a result of safety concerns surrounding COX-2s, CEO Thomas Ryan said during an earnings call Feb. 2. FDA's Arthritis Drug and Drug Safety & Risk Management advisory committees will evaluate COX-2 and NSAID safety during a meeting Feb. 16-18 (1"The Tan Sheet" Jan. 17, 2005, p. 9)...